Qumei Singba, China's 3 billion weight loss drug market who debut?

The core message: A recent notice from the State Food and Drug Administration will make a drastic change in the domestic market structure of 3 billion weight loss. Because sibutramine may cause harm to the cardiovascular system of the user, the risk of weight loss is greater than the efficacy. Sibutramine raw materials and 15 kinds of slimming drug preparations including sibutramine including Qumei, Aoquqing and Kexiu Production, sales and use are prohibited, and those already listed are recalled by the production company for destruction.

A recent notice from the State Food and Drug Administration will make a drastic change in the domestic market of 3 billion weight loss. Because sibutramine may cause harm to the cardiovascular system of the user, the risk of weight loss is greater than the efficacy. Sibutramine raw materials and 15 kinds of slimming drug preparations including sibutramine including Qumei, Aoquqing and Kexiu Production, sales and use are prohibited, and those already listed are recalled by the production company for destruction.

According to statistics, sibutramine products that have been in the market for 10 years in China's diet pill market accounted for 23% of the domestic diet pill market in 2008. This time, the market was emptied. On the one hand, Chongqing Zhien's forthcoming imitation of Roche Seneca's Seleccio was vacated. On the other hand, some health-care products that emphasize health care also had room to flex their muscles.

Weight-reducing drug market seat rearrangement

According to data from the Guangzhou punctuation medical information company of the Southern Food and Economic Research Institute of the State Food and Drug Administration (SFDA Southern Institute), the domestic market for weight-reducing drugs (prescription drugs) was 1.09 billion yuan last year, while the sales of Qumi and Seneco were respectively 897 million and 81 million, Qumei's average annual market share of 76.3%.

According to the promotional materials of the Taiji Group, Qumei has generated sales revenue of 5 billion yuan in the past 10 years, and the highest annual sales amounted to 400 million yuan. Qumei was created as a marketing myth in the diet pill industry. And because Sibutramine has ended its journey of life, it will affect Tai Chi Group's sales revenue of nearly 40 million yuan this year.

In the two major categories of weight loss adjunctive treatment drugs previously approved by the Food and Drug Administration, another representative of Orlistat is Roche Seneco, which in 2007 became the world’s best-selling diet pill. However, since Roche sold its global O TC business to Bayer in 2007, the retail channel has changed, so that Seneca is basically out of stock in the Chinese market. In May of this year, Seleccio copied by Chongqing Jien was not yet listed. According to industry sources, it is clear that organizing safe and effective new diet pills in the short term is not realistic. Even if new varieties of European and American products are introduced, they can only hopefully complete the introduction within one or two years.

Non-pharmaceutical Weight Loss Products Will Be "Popular"

However, China's weight loss market is growing at a geometric level, with more than 90 million obese patients, and weight loss products are increasing at a rate of over 20% per year, with total annual sales of up to 10 billion. The reporter learned that domestic weight-loss products consist of three major categories: tea-based health foods, medicines, external use and equipment. Health care products account for two-thirds of oral weight-loss products, and drugs account for one-third of the total. The SFD A South punctuation information retail monitoring data further shows that in 2008, the national retail drug market for slimming products was 3.254 billion, and in 2009 it was 3.156 billion. The delisting of sibutramine caused the weight loss market to vacate a huge gap. Moreover, because consumers generally believe that OTC is safer than prescription drugs, and health products are safer than OTC, weight loss products that focus on tea therapy clearly have favorable factors for gaining greater market share.

The reporter visited the supermarket and found that the main weight loss health care products market for tea therapy is mainly occupied by Pitt students and Big Impression. The former's flagship product, the Besunyen brand, is also the top three in market share for consecutive years. According to the official research report released by Besunyen before its listing in Hong Kong, Besunyen was the largest raw material buyer and largest supplier of health tea in the Chinese health tea market in terms of retail sales from 2008 to 2009. Last year’s market share was 18.8%. The second is only 5.5%. In the two years from 2007 to 2009, the composite annual growth rate of sales revenue and net profit of Bishengyuan also reached 99.1% and 72.5% respectively. Credit Suisse gave Pitts a rating of “Outperform” for the first time on the day before, and forecasted its compound annual growth rate of profit for the next three fiscal years to reach 27.4%, which is equivalent to 21.9 times forecast earnings for 2011. Although there is no actual data on the share expansion, but in the current weight-loss drug market without the first floor of the dragon, stressed that health + conditioning weight loss health products is undoubtedly waiting to seize the larger map.